Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Martinez Ledesma, Emmanuel ^a,b   Verhaak, Roeland G W ^b   Treviño, Victor ^a  

^a SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ALGORITHM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MORTALITY; NEOPLASMS; PREVALENCE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ALGORITHMS; BIOMARKERS, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84937910586     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11966     Document Type: Article

References (135)

1. Helpap, B. & Egevad, L. Modified Gleason grading. An updated review. Histol Histopathol 24, 661-666 (2009).
2. Astler, V. B. & Coller, F. A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139, 846-852 (1954).
3. Mutch, D. M., Berger, A., Mansourian, R., Rytz, A. & Roberts, M. A. Microarray data analysis: a practical approach for selecting differentially expressed genes. Genome Biol 2, PREPRINT0009 (2001).
4. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17, 1471-1474, doi: 10.1245/s10434-010-0985-4 (2010).
5. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477, doi: 10.1016/j.cell.2013.09.034 (2013).
6. Network, C. G. A. R. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615, doi: 10.1038/nature10166 (2011).
7. Network, C. G. A. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70, doi: 10.1038/nature11412 (2012).
8. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110, doi: 10.1016/j.ccr.2009.12.020 (2010).
9. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421, doi: 10.1038/nature12477 (2013).
10. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 45, 1134-1140, doi:10.1038/ng.2760 (2013).
11. Hamilton, M. P. et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun 4, 2730, doi:10.1038/ncomms3730 (2013).
12. Han, L. et al. The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun 5, 3963, doi:10.1038/ncomms4963 (2014).
13. Yu, X. et al. The pan-cancer analysis of gene expression patterns in the context of inflammation. Mol Biosyst 10, 2270-2276, doi:10.1039/c4mb00258j (2014).
14. Martinez, E. et al. Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene, doi:10.1038/onc.2014.216 (2014).
15. Hoadley, K. A. et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell 158, 929-944, doi:10.1016/j.cell.2014.06.049 (2014).
16. Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Communications 4, 11, doi:10.1038/ncomms3612 (2013).
17. Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19, 279-290, doi:10.1158/1078-0432.ccr-12-1558 (2013).
18. Rung, J. & Brazma, A. Reuse of public genome-wide gene expression data. Nat Rev Genet 14, 89-99, doi:10.1038/nrg3394 (2013).
19. Baker, M. Gene data to hit milestone. Nature News 487, 282, doi:doi:10.1038/487282a (2012).
20. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14, 518-527, doi:10.1038/nm1764 (2008).
21. Li, Z. et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31, 1172-1181, doi:10.1200/jco.2012.44.3184 (2013).
22. Chen, R. et al. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res 74, 2892-2902, doi:10.1158/0008-5472.can-13-2775 (2014).
23. Peng, Z. et al. An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis 17, 81-90, doi:10.1038/pcan.2013.57 (2014).
24. Verhaak, R. G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123, 517-525, doi:10.1172/jci65833 (2013).
25. Chibon, F. et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16, 781-787, doi:10.1038/nm.2174 (2010).
26. Maak, M. et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 257, 1053-1058, doi:10.1097/SLA.0b013e31827c1180 (2013).
27. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817-2826, doi:10.1056/NEJMoa041588 (2004).
28. Venet, D., Dumont, J. E. & Detours, V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7, e1002240, doi:10.1371/journal.pcbi.1002240 (2011).
29. Ein-Dor, L., Zuk, O. & Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 103, 5923-5928, doi:10.1073/pnas.0601231103 (2006).
30. Yuan, Y. et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol 32, 644-652, doi:10.1038/nbt.2940 (2014).
31. Daves, M. H., Hilsenbeck, S. G., Lau, C. C. & Man, T. K. Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics 4, 56, doi:10.1186/1755-8794-4-56 (2011).
32. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38, 1043-1048, doi:10.1038/ng1861 (2006).
33. Glinsky, G. V., Berezovska, O. & Glinskii, A. B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115, 1503-1521, doi:10.1172/jci23412 (2005).
34. Starmans, M. H. et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 99, 1884-1890, doi:10.1038/sj.bjc.6604746 (2008).
35. Wan, Y. W., Qian, Y., Rathnagiriswaran, S., Castranova, V. & Guo, N. L. A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types. Oncol Rep 24, 489-494 (2010).
36. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40, 499-507, doi:10.1038/ng.127 (2008).
37. Tibshirani, R., Hastie, T., Narasimhan, B. & Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. Jan 20; 99, 6567-6572 (2002).
38. Tibshirani, R. The lasso method for variable selection in the Cox model. Stat Med 16, 385-395 (1997).
39. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 67, 301-320, doi:10.1111/j.1467-9868.2005.00503.x (2005).
40. Yoshihara, K. et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 18, 1374-1385, doi:10.1158/1078-0432.ccr-11-2725 (2012).
41. Park, Y. Y. et al. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One 7, e44225, doi:10.1371/journal.pone.0044225 (2012).
42. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. Jan 20; 98, 5116-5121 (2001).
43. Stratford, J. K. et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 7, e1000307, doi:10.1371/journal.pmed.1000307 (2010).
44. Saeys, Y., Inza, I. & Larranaga, P. A review of feature selection techniques in bioinformatics. Bioinformatics 23, 2507-2517 (2007).
45. Moreau, Y. & Tranchevent, L. C. Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nat Rev Genet 13, 523-536, doi:10.1038/nrg3253 (2012).
46. Chuang, H. Y., Lee, E., Liu, Y. T., Lee, D. & Ideker, T. Network-based classification of breast cancer metastasis. Mol Syst Biol 3, 140, doi:10.1038/msb4100180 (2007).
47. Li, J., Roebuck, P., Grunewald, S. & Liang, H. SurvNet: a web server for identifying network-based biomarkers that most correlate with patient survival data. Nucleic Acids Res 40, W123-126, doi:10.1093/nar/gks386 (2012).
48. Wu, G. & Stein, L. A network module-based method for identifying cancer prognostic signatures. Genome Biol 13, R112, doi:10.1186/gb-2012-13-12-r112 (2012).
49. Winter, C. et al. Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol 8, e1002511, doi:10.1371/journal.pcbi.1002511 (2012).
50. Taylor, I. W. et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27, 199-204, doi:10.1038/nbt.1522 (2009).
51. Li, J. et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun 1, 34, doi:10.1038/ncomms1033 (2010).
52. Keshava Prasad, T. S. et al. Human Protein Reference Database - 2009 update. Nucleic Acids Res 37, D767-772, doi:10.1093/nar/gkn892 (2009).
53. Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113-1120, doi:10.1038/ng.2764 (2013).
54. Bradburn, M. J., Clark, T. G., Love, S. B. & Altman, D. G. Survival analysis part II: multivariate data analysis - an introduction to concepts and methods. Br J Cancer 89, 431-436, doi:10.1038/sj.bjc.6601119 (2003).
55. Harrell, F. E., Lee, K. L. & Mark, D. B. Multivariable Prognostic Models: Issues In Developing Models, Evaluating Assumptions And Adequacy, And Measuring And Reducing Errors. Statistics in Medicine 15, 361-387 (1996).
56. Aguirre-Gamboa, R. et al. SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis. PLoS One 8, e74250, doi:10.1371/journal.pone.0074250 (2013).
57. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545-15550 (2005).
58. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57, doi:10.1038/nprot.2008.211 (2009).
59. Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549, doi:10.1038/nrc2694 (2009).
60. Hardie, D. G. & Alessi, D. R. LKB1 and AMPK and the cancer-metabolism link-ten years after. BMC Biol 11, 36, doi:10.1186/1741-7007-11-36 (2013).
61. Deroo, B. J. & Korach, K. S. Estrogen receptors and human disease. J Clin Invest 116, 561-570, doi:10.1172/jci27987 (2006).
62. Molloy, N. H., Read, D. E. & Gorman, A. M. Nerve growth factor in cancer cell death and survival. Cancers (Basel) 3, 510-530, doi:10.3390/cancers3010510 (2011).
63. Li, L. & Davie, J. R. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192, 275-283, doi:10.1016/j. aanat.2010.07.010 (2010).
64. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
65. Yu, K. et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet 4, e1000129, doi:10.1371/journal.pgen.1000129 (2008).
66. Cheng, W. Y., Ou Yang, T. H. & Anastassiou, D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 9, e1002920, doi:10.1371/journal.pcbi.1002920 (2013).
67. Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2, 63ra94, doi:10.1126/scitranslmed.3001375 (2010).
68. Pinto-Leite, R. et al. Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer. Tumour Biol 35, 4599-4617, doi:10.1007/s13277-013-1604-3 (2014).
69. Yu, J. et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13, 7296-7304, doi:10.1158/1078-0432.ccr-07-0861 (2007).
70. Sahlberg, S. H., Spiegelberg, D., Glimelius, B., Stenerlow, B. & Nestor, M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One 9, e94621, doi:10.1371/journal. pone.0094621 (2014).
71. Shin, S., Rossow, K. L., Grande, J. P. & Janknecht, R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 67, 7572-7578, doi:10.1158/0008-5472.can-06-4652 (2007).
72. Ladner, R. D. et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 60, 3493-3503 (2000).
73. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res 41, D816-823, doi:10.1093/nar/gks1158 (2013).
74. Turinsky, A. L., Razick, S., Turner, B., Donaldson, I. M. & Wodak, S. J. Navigating the global protein-protein interaction landscape using iRefWeb. Methods Mol Biol 1091, 315-331, doi:10.1007/978-1-62703-691-7-22 (2014).
75. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41, D808-815, doi:10.1093/nar/gks1094 (2013).
76. Arnold, P., Erb, I., Pachkov, M., Molina, N. & van Nimwegen, E. MotEvo: integrated Bayesian probabilistic methods for inferring regulatory sites and motifs on multiple alignments of DNA sequences. Bioinformatics 28, 487-494, doi:10.1093/bioinformatics/btr695 (2012).
77. Ojesina, A. I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-+, doi:10.1038/nature12881 (2014).
78. Griffith, M. et al. DGIdb: mining the druggable genome. Nat Methods 10, 1209-1210, doi:10.1038/nmeth.2689 (2013).
79. Pandey, S. N., Dixit, M., Choudhuri, G. & Mittal, B. Lipoprotein receptor associated protein (LRPAP1) insertion/deletion polymorphism: association with gallbladder cancer susceptibility. Int J Gastrointest Cancer 37, 124-128, doi:10.1007/s12029-007-9002-y (2006).
80. Chin, Y. R., Yuan, X., Balk, S. P. & Toker, A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov 4, 942-955, doi:10.1158/2159-8290.cd-13-0873 (2014).
81. Wakefield, A. et al. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res 73, 745-755, doi:10.1158/0008-5472.can-12-1321 (2013).
82. Bandini, S. et al. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncoimmunology 2, e26137, doi:10.4161/onci.26137 (2013).
83. Chien, W. et al. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 38, 1741-1747, doi:10.3892/ijo.2011.985 (2011).
84. Mazurek, A. et al. DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov 2, 812-825, doi:10.1158/2159-8290.cd-12-0116 (2012).
85. Holst, F. et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39, 655-660, doi:10.1038/ng2006 (2007).
86. Mange, A. et al. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res 18, 1992-2000, doi:10.1158/1078-0432.ccr-11-2527 (2012).
87. Langer, S. et al. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol 27, 345-352 (2006).
88. Sum, E. Y. et al. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci USA 102, 7659-7664, doi:10.1073/pnas.0502990102 (2005).
89. Bauer, J. A. et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 16, 681-690, doi:10.1158/1078-0432.ccr-09-1091 (2010).
90. Natarajan, T. G. et al. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int 10, 13, doi:10.1186/1475-2867-10-13 (2010).
91. Rizki, A. et al. A human breast cell model of preinvasive to invasive transition. Cancer Res 68, 1378-1387, doi:10.1158/0008-5472.can-07-2225 (2008).
92. Moody, S. E. et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 0, doi:10.1038/onc.2014.153 (2014).
93. Stratford, A. L. et al. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 30, 1338-1348, doi:10.1002/stem.1128 (2012).
94. Reinholz, M. M. et al. Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Breast Cancer Res Treat 86, 75-88, doi:10.1023/B:BREA.0000032926.74216.7d (2004).
95. Slyskova, J. et al. Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. Clin Cancer Res 18, 5878-5887, doi:10.1158/1078-0432.ccr-12-1380 (2012).
96. Zhang, J. T. et al. Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta 1833, 2961-2969, doi:10.1016/j.bbamcr.2013.07.021 (2013).
97. Ahmed, D. et al. A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clin Transl Gastroenterol 3, e27, doi:10.1038/ctg.2012.21 (2012).
98. Bae, J. A. et al. An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells. Clin Cancer Res 20, 4115-4128, doi:10.1158/1078-0432.ccr-13-2863 (2014).
99. Nagy, N. et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50, 392-401 (2002).
100. Slattery, M. L., Lundgreen, A., Herrick, J. S. & Wolff, R. K. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res 706, 13-20, doi:10.1016/j.mrfmmm.2010.10.005 (2011).
101. Grabowski, P. et al. Heterogeneous expression of neuroendocrine marker proteins in human undifferentiated carcinoma of the colon and rectum. Ann N Y Acad Sci 1014, 270-274 (2004).
102. Spisak, S. et al. Applicability of antibody and mRNA expression microarrays for identifying diagnostic and progression markers of early and late stage colorectal cancer. Dis Markers 28, 1-14, doi:10.3233/dma-2010-0677 (2010).
103. Maldonado, V. & Melendez-Zajgla, J. Role of Bcl-3 in solid tumors. Mol Cancer 10, 152, doi:10.1186/1476-4598-10-152 (2011).
104. Weber, R. G., Rieger, J., Naumann, U., Lichter, P. & Weller, M. Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. Int J Cancer 91, 213-218 (2001).
105. Romao, L. F. et al. Connective tissue growth factor (CTGF/CCN2) is negatively regulated during neuron-glioblastoma interaction. PLoS One 8, e55605, doi:10.1371/journal.pone.0055605 (2013).
106. Nicolasjilwan, M. et al. Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. J Neuroradiol, doi:10.1016/j.neurad.2014.02.006 (2014).
107. Russo, A. & O'Bryan, J. P. Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene 31, 4828-4834, doi:10.1038/onc.2011.643 (2012).
108. Qiang, L. et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279, 13-21, doi:10.1016/j.canlet.2009.01.016 (2009).
109. Beghini, A. et al. The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene 22, 2581-2591 (2003).
110. Chang, C. C. et al. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res 73, 4147-4157, doi:10.1158/0008-5472.can-12-4085 (2013).
111. Rampias, T. et al. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res 20, 2933-2946, doi:10.1158/1078-0432.ccr-13-2721 (2014).
112. Menendez, S. T. et al. Frequent aberrant expression of the human ether a go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications. J Mol Med (Berl) 90, 1173-1184, doi:10.1007/s00109-012-0893-0 (2012).
113. Muro-Cacho, C. A., Rosario-Ortiz, K., Livingston, S. & Munoz-Antonia, T. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin Cancer Res 7, 1618-1626 (2001).
114. Tan, W. et al. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol 186, 2071-2077, doi:10.1016/j.juro.2011.06.049 (2011).
115. Penzvalto, Z. et al. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One 8, e59503, doi:10.1371/journal.pone.0059503 (2013).
116. Spitz, M. R. et al. Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to secondhand smoke. Cancer Discov 1, 420-429, doi:10.1158/2159-8290.cd-11-0080 (2011).
117. Chang, C. C. et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96, 364-375 (2004).
118. Lu, Y. et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3, e467, doi:10.1371/journal.pmed.0030467 (2006).
119. Karachaliou, N. et al. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol 8, 295-300, doi:10.1097/JTO.0b013e31827db621 (2013).
120. Meng, H. et al. Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res 17, 2426-2433, doi:10.1158/1078-0432.ccr-10-2385 (2011).
121. Kobayashi, K. et al. Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo. Oncogene 23, 3089-3096, doi:10.1038/sj.onc.1207433 (2004).
122. Jin, Y. et al. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. Int J Cancer 134, 2294-2304, doi:10.1002/ijc.28568 (2014).
123. Lara, R. et al. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene 30, 3513-3521, doi:10.1038/onc.2011.61 (2011).
124. Szymanowska-Narloch, A. et al. Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients. Adv Med Sci 58, 196-206, doi:10.2478/ams-2013-0025 (2013).
125. Rolle, C. E. et al. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther 13, 576-584, doi:10.1158/1535-7163.mct-13-0109 (2014).
126. Kikuchi, R. et al. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 67, 7095-7105, doi:10.1158/0008-5472.can-06-4567 (2007).
127. Darb-Esfahani, S. et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer 16, 1229-1239, doi:10.1677/erc-08-0338 (2009).
128. Neyns, B. et al. Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene 12, 1247-1257 (1996).
129. Wang, H. et al. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer. Hum Pathol 45, 401-408, doi:10.1016/j.humpath.2013.10.005 (2014).
130. Isaksson, H. S., Sorbe, B. & Nilsson, T. K. Whole genome expression profiling of blood cells in ovarian cancer patients-Prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14. Oncotarget 5, 4040-4049 (2014).
131. Wang, Y. et al. Ras-induced epigenetic inactivation of the RRAD (Ras-related associated with diabetes) gene promotes glucose uptake in a human ovarian cancer model. J Biol Chem 289, 14225-14238, doi:10.1074/jbc.M113.527671 (2014).
132. Davies, S. et al. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep 25, 855-862, doi:10.3892/or.2011.1147 (2011).
133. Li, L. & Guan, K. L. Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem 288, 703-708, doi:10.1074/jbc.C112.396903 (2013).
134. Pressinotti, N. C. et al. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low-and highrisk prostate cancer. Mol Cancer 8, 130, doi:10.1186/1476-4598-8-130 (2009).
135. Ito, R. et al. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma. Biol Pharm Bull 27, 315-318 (2004).